Is peri-transplant blood transfusion associated with worse transplant outcomes? A retrospective study

Table 3 Infectious and non-infectious complications among the two groups, n (%)

	Total, 105	Non-transfusion, 51 (48.6%)	Transfusion, 54 (51.4%)	P value
No. of infections	0 (0-1)	1 (0-1)	0 (0-1.25)	0.554
Types of infections
none	55 (52.4)	25 (49)	30 (55.6)	0.745
UTI	30 (28.6)	14 (27.5)	16 (29.6)	0.832
Pnemonia	1 (1)	1 (2)	0 (0)	0.486
TB	1 (1)	0 (0)	1 (1.9)	1
BK	7 (6.7)	5 (9.8)	2 (3.7)	0.261
Bactremia	4 (3.8)	1 (2)	3 (5.6)	0.618
Epidediymo-orchitis	2 (1.9)	1 (2)	1 (1.9)	1
Gastroenteritis	2 (1.9)	2 (3.9)	0 (0)	0.234
Herpes zoster	1 (1)	0 (0)	1 (1.9)	1
Infected AVF	1 (1)	1 (2)	0 (0)	0.486
Perianal abcess	1 (1)	1 (2)	0 (0)	0.486
COVID-19	9 (8.6)	6 (11.8)	3 (5.6)	0.311
URTI	2 (1.9)	1 (2)	1 (1.9)	1
CMV	12 (11.4)	6 (11.8)	6 (11.1)	1
Urological complications
None	95 (90.5)	49 (96.1)	46 (85.2)	0.484
Allograft artery stenosis	1 (1)	0 (0)	1 (1.9)
Collection	3 (2.9)	1 (2)	2 (3.7)
Lymphocele	1 (1)	0 (0)	1 (1.9)
Obstrctive uropathy	1 (1)	0 (0)	1 (1.9)
Perinephric collection and ureteric stricture	2 (1.9)	0 (0)	2 (3.7)
Unrogenic bladder	1 (1)	0 (0)	1 (1.9)
Urinary leak	1 (1)	1 (2)	0 (0)
Urological complications
No	95 (90.5)	49 (96.1)	46 (85.2)	0.094
Yes	10 (9.5)	2 (3.9)	8 (14.8)
CNI withdrawal	1 (1)	0 (0)	1 (1.9)	1
Duration from Tx	3 d
MMF withdrawal	1 (1)	0 (0)	1 (1.9)	1
Duration from Tx	3 d
Steroids withdrawal	0 (0)	0 (0)	0 (0)

UTI: Urinary tract infection; TB: Tuberculosis; AVF: Arterio-venous fistula; COVID-19: Coronavirus disease 2019; URTI: Upper respiratory tract infection; CMV: Cytomegalovirus; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil.